Mehmet Oz has committed to defending Medicare drug price negotiations in court if he is confirmed to lead CMS.

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

The UK government is planning to double the proportion of money drugmakers have to pay back on medicine sales to the National ...

Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO, as the company reported record-high revenues on ...

HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to ...

Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away ...

Pfizer's pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a ...

Celeste Warren said in a LinkedIn post that she is retiring from Merck on July 7. Warren joined Merck in 1997 and has been VP ...